---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-004805"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:39:56.844329+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Cytek Biosciences prelim FY2023 revenue near high end of $188M-$192M guidance

## Summary
- Preliminary full-year 2023 revenue expected near high end of prior guidance range of $188M-$192M.
- Final Q4 and FY2023 results and 2024 guidance to be reported on expected earnings call in late February 2024.
- CEO Wenbin Jiang to present at 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024.

## SEC filing metadata
- accession: 0001193125-24-004805
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312524004805/0001193125-24-004805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312524004805/d690054d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-004805
- JSON: https://secwatch.observer/filing/0001193125-24-004805.json
- Plain text: https://secwatch.observer/filing/0001193125-24-004805.txt

## Key facts
- Earnings Releases
  Cytek Biosciences, Inc. reported preliminary financial results for the full year ended December 31, 2023.
  - Period: the full year ended December 31, 2023
  - Result: preliminary results
  source text: Cytek expects its full year revenue for 2023 to be near the high end of the company’s most recent revenue guidance range of $188 million to $192 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312524004805/0001193125-24-004805-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.